Rongzhen Xu
YOU?
Author Swipe
View article: In vivo vaccine generation with a topical small molecule cocktail to eradicates AML and PDAC
In vivo vaccine generation with a topical small molecule cocktail to eradicates AML and PDAC Open
Using vaccine to cure cancer has been expected for over 130 years, but remains a big challenge. Here we present a novel in vivo personal and off-the-shelf vaccine generation strategy with unique mechanism, which is very simple but high eff…
View article: HERV‐K TM Subunit Elicits CD8<sup>+</sup> T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC
HERV‐K TM Subunit Elicits CD8<sup>+</sup> T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC Open
CD8 + T cell anergy is a critical driver of cancer immune evasion, but the underlying causes and mechanisms remain elusive. Here, the functional human endogenous retroviruses‐K envelope (HERV‐K Env) subunit transmembrane (K‐TM) is identifi…
View article: The Influence of Cross-Cultural Psychological Mechanism
The Influence of Cross-Cultural Psychological Mechanism Open
Cross-cultural psychology, as a discipline that studies human psychological characteristics and behavioral differences under different cultural backgrounds, has attracted wide attention in recent years. This paper aims to explore the influ…
View article: Corrigendum: Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer
Corrigendum: Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer Open
[This corrects the article DOI: 10.3389/fimmu.2024.1533740.].
View article: Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer
Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer Open
Immune dysfunction is one of the hallmarks of cancer and plays critical roles in immunotherapy resistance, but there is no serum biomarker that can be used to evaluate immune-dysfunction status of cancer patients. Here, we identified subty…
View article: Extensively Targeted Metabolomics Combined with Transcriptomics Reveals Nonvolatile Metabolic Changes During Major Processing of Beauty Tea
Extensively Targeted Metabolomics Combined with Transcriptomics Reveals Nonvolatile Metabolic Changes During Major Processing of Beauty Tea Open
View article: Extensively Targeted Metabolomics Combined with Transcriptomics Reveals Nonvolatile Metabolic Changes During Major Processing of Beauty Tea
Extensively Targeted Metabolomics Combined with Transcriptomics Reveals Nonvolatile Metabolic Changes During Major Processing of Beauty Tea Open
View article: Subtype-specific HERV-K102 envelope is a novel serum immunosuppressive biomarker and therapeutic target of cancer
Subtype-specific HERV-K102 envelope is a novel serum immunosuppressive biomarker and therapeutic target of cancer Open
Background: Immune dysfunction is a hallmark of cancer and plays critical roles in immunotherapy resistance, but there is no serum biomarker that can be used to evaluate immune-dysfunction status of cancer patients. Here, we identified sub…
View article: Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes
Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes Open
Chromosomal instability is a prominent biological feature of myelodysplastic syndromes (MDS), with over 50% of patients with MDS harboring chromosomal abnormalities or a complex karyotype (CK). Despite this observation, the mechanisms unde…
View article: Targeting CaMKII-δ/DHCR24 axis is a novel strategy against acute myeloid leukemia
Targeting CaMKII-δ/DHCR24 axis is a novel strategy against acute myeloid leukemia Open
Relapse is one of the biggest challenges in treating acute myeloid leukemia (AML) due to leukemia stem/progenitor cells resisting chemotherapy, providing a cellular reservoir to form the basis for relapse. Here, we identify CaMKII-δ/DHCR24…
View article: An oral triple pill-based cocktail effectively controls acute myeloid leukemia with high translation
An oral triple pill-based cocktail effectively controls acute myeloid leukemia with high translation Open
Acute myeloid leukemia (AML) is a deadly hematological malignancy characterized by oncogenic translational addiction that results in over-proliferation and apoptosis evasion of leukemia cells. Various chemo- and targeted therapies aim to r…
View article: Co‐Targeting c‐Myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models
Co‐Targeting c‐Myc and Bcl‐2 by Oral Small Molecule Combination of WBC100 and Venetoclax Effectively Controls Acute Myeloid Leukemia in Preclinical Models Open
Uncontrolled proliferation and apoptosis evasion are two hallmarks of acute myeloid leukemia (AML), but the molecular mechanisms remain poorly understood. In this study, it is demonstrated that the double over‐expresser of oncoprotein c‐My…
View article: An oral triple pill-based cocktail effectively controls acute myeloid leukemia with high translation
An oral triple pill-based cocktail effectively controls acute myeloid leukemia with high translation Open
Acute myeloid leukemia (AML) is a deadly hematological malignancy characterized by oncogenic translational addiction that results in over-proliferation and apoptosis evasion of leukemia cells. Various chemo- and targeted-therapies aimed at…
View article: Supplementary Table 1 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 1 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 9K, IC50s of berbamine on liver cancer cells.
View article: Supplementary Table 2 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 2 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 11K, Sphere formation (2 independent trials).
View article: Data from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Data from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer …
View article: Supplementary Figure Legends from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Figure Legends from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
PDF file, 51K.
View article: Data from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Data from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer …
View article: Supplementary Table 1 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 1 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 9K, IC50s of berbamine on liver cancer cells.
View article: Supplementary Figures from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Figures from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
PDF file, 1752K, Figure S1. (Related to Figure 2) BBM suppresses the xenograft growth of Huh7 and SK-Hep-1 cells; Figure S2. (Related to Figure 3) BBM is localized in cytoplasm and affects cell survival; Figure S3. (Related to Figure 4) BB…
View article: Supplementary Table 3 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 3 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 12K, Phosphorylation of CAMKII in liver cancer patients.
View article: Supplementary Table 2 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 2 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 11K, Sphere formation (2 independent trials).
View article: Supplementary Figure Legends from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Figure Legends from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
PDF file, 51K.
View article: Supplementary Figures from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Figures from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
PDF file, 1752K, Figure S1. (Related to Figure 2) BBM suppresses the xenograft growth of Huh7 and SK-Hep-1 cells; Figure S2. (Related to Figure 3) BBM is localized in cytoplasm and affects cell survival; Figure S3. (Related to Figure 4) BB…
View article: Supplementary Table 3 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II
Supplementary Table 3 from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase II Open
XLSX file, 12K, Phosphorylation of CAMKII in liver cancer patients.
View article: Identification of Monobenzone as a Novel Potential Anti-Acute Myeloid Leukaemia Agent That Inhibits RNR and Suppresses Tumour Growth in Mouse Xenograft Model
Identification of Monobenzone as a Novel Potential Anti-Acute Myeloid Leukaemia Agent That Inhibits RNR and Suppresses Tumour Growth in Mouse Xenograft Model Open
Acute myeloid leukaemia (AML) is one of the most common types of haematopoietic malignancy. Ribonucleotide reductase (RNR) is a key enzyme required for DNA synthesis and cell proliferation, and its small subunit RRM2 plays a key role for t…
View article: Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells Open
Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly t…
View article: Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma Open
Tumor protein 53 ( TP53 ) mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B m…
View article: Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins
Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins Open
View article: Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling
Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling Open
Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD AML) is a subset of highly aggressive malignancies with poor clinical outcome. Despite some advances in the development of FLT3 tyrosine k…